News
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...
7d
Dealbreaker on MSNSanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio
The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...
PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...
Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...
13h
New Scientist on MSNHuman trials point the way towards an mRNA vaccine against HIV
We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...
5d
News-Medical.Net on MSNNew model predicts mRNA protein production, accelerating drug and vaccine discovery
A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently ...
Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...
French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results